Mutations in GNA11 in uveal melanoma

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Uveal melanoma is the most common primary intraocular cancer.
• Effective therapies for metastatic uveal melanoma are lacking.
• Mutations in the GNAQ gene are identified in 40% of uveal melanomas.

Purpose of the Study:

• To investigate the role of GNAQ and GNA11 gene mutations in melanocytic neoplasms.
• To determine the prevalence of GNAQ and GNA11 mutations in uveal melanoma and its metastases.
• To explore the functional consequences of GNA11 mutations in a mouse model.

Main Methods:

• Sequencing of GNAQ and GNA11 genes (exons 4 and 5, and all coding exons) in 713 melanocytic neoplasms.
• Analysis of mutation patterns in uveal melanomas, blue nevi, and other melanomas.
• In vivo studies using a mouse model to assess the oncogenic potential of GNA11 mutations.

Main Results:

• Somatic mutations in GNAQ and GNA11 (affecting Q209 or R183) were found in a mutually exclusive pattern.
• Q209 mutations in GNA11 were present in 32% of primary uveal melanomas and 57% of metastases.
• Q209 mutations in GNAQ were found in 45% of uveal melanomas and 22% of metastases.
• Mutations in GNA11 induced metastatic tumors in mice and activated the MAPK pathway.

Conclusions:

• 83% of analyzed uveal melanomas harbored somatic mutations in GNAQ or GNA11.
• Constitutive activation of the GNAQ/GNA11 pathway is a significant factor in uveal melanoma development.
• These findings highlight GNAQ and GNA11 as potential therapeutic targets for uveal melanoma.